IRIS Institutional Research Information System - OPENBS Open Archive UniBS

GIACOMINI, ARIANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.608
EU - Europa 2.489
AS - Asia 2.286
SA - Sud America 451
Continente sconosciuto - Info sul continente non disponibili 185
AF - Africa 55
OC - Oceania 9
Totale 11.083
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.485
SG - Singapore 795
PL - Polonia 754
CN - Cina 690
IT - Italia 430
BR - Brasile 370
UA - Ucraina 309
DE - Germania 286
HK - Hong Kong 237
FI - Finlandia 187
VN - Vietnam 183
GB - Regno Unito 114
FR - Francia 96
BD - Bangladesh 87
TR - Turchia 79
RU - Federazione Russa 71
CA - Canada 70
IE - Irlanda 67
IN - India 64
SE - Svezia 38
AR - Argentina 31
NL - Olanda 28
ID - Indonesia 25
JP - Giappone 25
ES - Italia 24
MX - Messico 24
IQ - Iraq 23
CZ - Repubblica Ceca 22
BE - Belgio 19
ZA - Sudafrica 19
EC - Ecuador 14
AT - Austria 10
SA - Arabia Saudita 10
PK - Pakistan 9
UZ - Uzbekistan 8
VE - Venezuela 8
CH - Svizzera 7
MA - Marocco 7
NG - Nigeria 7
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
CL - Cile 6
CR - Costa Rica 6
EU - Europa 6
PE - Perù 6
UY - Uruguay 6
AU - Australia 5
JM - Giamaica 5
PY - Paraguay 5
TH - Thailandia 5
AZ - Azerbaigian 4
BG - Bulgaria 4
CO - Colombia 4
KE - Kenya 4
LT - Lituania 4
MY - Malesia 4
PH - Filippine 4
TT - Trinidad e Tobago 4
EG - Egitto 3
GD - Grenada 3
GR - Grecia 3
HR - Croazia 3
JO - Giordania 3
KR - Corea 3
KZ - Kazakistan 3
LK - Sri Lanka 3
BH - Bahrain 2
BY - Bielorussia 2
CY - Cipro 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GE - Georgia 2
IL - Israele 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PA - Panama 2
PT - Portogallo 2
RO - Romania 2
SV - El Salvador 2
ZM - Zambia 2
AO - Angola 1
BB - Barbados 1
BO - Bolivia 1
DK - Danimarca 1
GA - Gabon 1
GT - Guatemala 1
HU - Ungheria 1
IR - Iran 1
KG - Kirghizistan 1
KH - Cambogia 1
KI - Kiribati 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
MG - Madagascar 1
MU - Mauritius 1
NO - Norvegia 1
NR - Nauru 1
OM - Oman 1
PR - Porto Rico 1
Totale 10.899
Salva come PNG Salva come JPEG
Città #
Warsaw 749
Ashburn 599
Fairfield 543
Singapore 462
Woodbridge 335
Hong Kong 237
Houston 224
Jacksonville 221
Cambridge 214
San Jose 211
Seattle 191
The Dalles 188
Wilmington 184
Brescia 176
Chandler 170
Beijing 160
New York 160
Ann Arbor 145
Los Angeles 143
Helsinki 137
Princeton 116
Dallas 98
Council Bluffs 92
Munich 78
Dearborn 76
Dublin 65
Lauterbourg 62
San Francisco 62
Istanbul 58
Chicago 55
Ho Chi Minh City 53
Nanjing 51
Santa Clara 46
Orem 45
São Paulo 43
Denver 42
Hanoi 37
Dong Ket 35
Des Moines 34
Redondo Beach 34
Montreal 33
Atlanta 30
Buffalo 30
Columbus 29
Shanghai 29
San Diego 28
Milan 27
Phoenix 27
Brooklyn 26
London 26
Nanchang 25
Moscow 22
Tokyo 22
Shenyang 21
Boston 20
Turku 19
Brussels 18
Jakarta 18
Jinan 18
Brno 17
Amsterdam 16
Changsha 16
Chennai 16
Toronto 16
Hebei 14
Guangzhou 13
Rio de Janeiro 13
Stockholm 13
Verona 13
Frankfurt am Main 12
Tianjin 12
Johannesburg 11
Tampa 11
Baghdad 10
Belo Horizonte 10
Dhaka 10
Jiaxing 10
Kocaeli 10
Lappeenranta 10
Manchester 10
Boardman 9
Charlotte 9
Washington 9
Da Nang 8
Falkenstein 8
Hefei 8
Lanzhou 8
Mexico City 8
Nuremberg 8
Raleigh 8
Tashkent 8
Haikou 7
Hangzhou 7
Ningbo 7
Porto Alegre 7
Turin 7
Abuja 6
Campinas 6
Curitiba 6
Kunming 6
Totale 7.512
Salva come PNG Salva come JPEG
Nome #
Cannabidiol alters mitochondrial bioenergetics via VDAC1 and triggers cell death in hormone-refractory prostate cancer 902
Brain angioarchitecture and intussusceptive microvascular growth in a murine model of Krabbe disease 380
U94 of human herpesvirus 6 down-modulates Src, promotes a partial mesenchymal-to-epithelial transition and inhibits tumor cell growth, invasion and metastasis 344
Blocking the FGF/FGFR system as a "two-compartment" antiangiogenic/antitumor approach in cancer therapy. 308
A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers 304
Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors 291
Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34(+) cells. 251
Long pentraxin-3 follows and modulates bladder cancer progression 225
Long Pentraxin-3 As An Epithelial-Stromal Fibroblast Growth Factor-Targeting Inhibitor In Prostate Cancer. 208
Stromal delivery of long Pentraxin-3 impairs FGF/FGFR-dependent tumor growth and metastasis 204
Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells. 203
The Antitumor Didox Acts as an Iron Chelator in Hepatocellular Carcinoma Cells 199
Long Pentraxin 3-Mediated Fibroblast Growth Factor Trapping Impairs Fibrosarcoma Growth 194
The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. 191
Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy 188
Antiangiogenic effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, mediated by AMPK activation. 185
Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach 185
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia 172
Circulating microRNAs and Their Role in Multiple Myeloma 170
Long pentraxin 3: A novel multifaceted player in cancer 169
Stromal delivery of long Pentraxin-3 impairs FGF/FGFR-dependent tumor growth and metastasis 163
Future applications of FGF/FGFR inhibitors in cancer 159
Combining vascular disruption activity of TRAIL-expressing CD34+ cells with antiangiogenic activity of sorafenib improves regression of tumor growth 155
Inhibition of angiogenesis by β-galactosylceramidase deficiency in globoid cell leukodystrophy 153
Inhibition of dna repair mechanisms and induction of apoptosis in triple negative breast cancer cells expressing the human herpesvirus 6 u94 151
Human CD34 + cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature 148
Discovery of novel FGF trap small molecules endowed with anti-myeloma activity 146
The autocrine fgf/fgfr system in both skin and uveal melanoma: Fgf trapping as a possible therapeutic approach 145
Hyperactive Akt1 Signaling Increases Tumor Progression and DNA Repair in Embryonal Rhabdomyosarcoma RD Line and Confers Susceptibility to Glycolysis and Mevalonate Pathway Inhibitors 143
A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments 141
β-Galactosylceramidase Deficiency Causes Bone Marrow Vascular Defects in an Animal Model of Krabbe Disease 141
FGFR blockade by pemigatinib treats naïve and castration resistant prostate cancer 140
Quantification of 3D Brain Microangioarchitectures in an Animal Model of Krabbe Disease 138
Uptake Profiles of Human Serum Exosomes by Murine and Human Tumor Cells through Combined Use of Colloidal Nanoplasmonics and Flow Cytofluorimetric Analysis 137
sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib 135
(3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapies 134
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells 134
FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress 133
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts 129
Stromal expression of long Pentraxin-3 impairs tumor growth and metastasis 122
Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer 122
Targeting the Endothelin-1 Receptors Curtails Tumor Growth and Angiogenesis in Multiple Myeloma 121
Halting the FGF/FGFR axis leads to anti-tumor activity in Waldenström's Macroglobulinemia by silencing MYD88 121
Potent in vivo anti-tumor activity of extracellular vesicles isolated from genetically engineered primary mesenchymal stromal cells expressing the trans-membrane TNF-Related Apoptosis-Inducing Ligand (TRAIL) 115
Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34⁺ cells in a xenograft model 115
Vascular amounts and dispersion of caliber-classified vessels as key parameters to quantitate 3D micro-angioarchitectures in multiple myeloma experimental tumors 114
Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma 113
Iron supplementation enhances RSL3-induced ferroptosis to treat naïve and prevent castration-resistant prostate cancer 113
Pentraxin 3 inhibits the angiogenic potential of multiple myeloma cells 110
Glyco-Coated CdSe/ZnS Quantum Dots as Nanoprobes for Carbonic Anhydrase IX Imaging in Cancer Cells 109
Inhibition of the FGF/FGFR System Induces Apoptosis in Lung Cancer Cells via c-Myc Downregulation and Oxidative Stress 107
The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancer 106
PTX3 Modulates Neovascularization and Immune Inflammatory Infiltrate in a Murine Model of Fibrosarcoma 105
β-Galactosylceramidase Promotes Melanoma Growth via Modulation of Ceramide Metabolism 99
FGF-trapping hampers cancer stem-like cells in uveal melanoma 98
The FGF/FGFR System in the Physiopathology of the Prostate Gland 97
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma 93
Design, synthesis, in vitro and in vivo biological evaluation of 2-amino-3-aroylbenzo[b]furan derivatives as highly potent tubulin polymerization inhibitors 91
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited anti-tumor activity 90
Human CD34+ Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Exert a Potent Anti-Lymphoma Effects by Targeting Tumor Vasculature 84
The natural FGF-trap long pentraxin 3 inhibits lymphangiogenesis and lymphatic dissemination 79
Post-transplant evaluation of bone marrow hematopoietic function in patients receiving high-dose Yttrium-90-Ibritumomab Tiuxetan (Zevalin) with autograft 79
Turn-Adopting Peptidomimetic as a Formyl Peptide Receptor-1 Antagonist 74
Proteasome inhibitors as anticancer agents 74
Targeting TRAIL Receptors with Genetically-Engineered CD34+ Hematopoietic Stem Cells 74
The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients 72
An ureido-substituted benzenesulfonamide carbonic anhydrase inhibitor exerts a potent antitumor effect in vitro and in vivo 71
FGF/FGFR inhibitors downmodulates c-Myc oncoprotein and hampers the growth of adrenocortical carcinoma 68
Preclinical Rationale for the Use of the Multikinase Inhibitor Sorafenib in the Treatment of Human Lymphomas 67
The histone deacetylase inhibitor ITF2357 (Givinostat) promotes Burkitt’s lymphoma cell line death modulating micro-RNA and Tissue Transglutaminase 2 expression 66
Preclinical Rationale for the Use of the Combined Treatment with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Hodgkin Lymphoma 63
Monoclonal antibodies for targeted treatment of lymphoproliferative neoplasias 45
Cancer Stem-like Cells: a new therapeutic target for the treatment of metastatic uveal melanoma 8
Totale 11.083
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.495
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.495
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022555 0 79 29 21 20 40 38 42 16 74 46 150
2022/2023497 80 15 29 29 43 120 6 51 68 1 37 18
2023/2024615 42 13 96 27 20 101 22 26 125 24 17 102
2024/20251.351 21 23 14 198 131 140 118 81 146 88 229 162
2025/20263.244 303 369 202 421 344 230 458 120 160 262 140 235
2026/2027822 708 114 0 0 0 0 0 0 0 0 0 0
Totale 11.083